NCT06498687 is a Phase 1 clinical trial of CYR-064 in Hyposmia, sponsored by University of Nebraska.

Who is sponsoring NCT06498687?

NCT06498687 is sponsored by University of Nebraska.

What drugs are being tested in NCT06498687?

Interventions in NCT06498687: CYR-064.

What condition does NCT06498687 study?

NCT06498687 studies Hyposmia, Anosmia.

Is NCT06498687 still recruiting?

NCT06498687 is currently withdrawn. Last updated 12 March 2025.

Last reviewed 2025-03-12 · How we verify

NCT06498687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-Arm Study to Evaluate the Feasibility of CYR-064 Theophylline Nasal Spray for the Treatment of Parkinson's Disease Related Hyposmia and Anosmia

Withdrawn Phase 1 Last updated 12 March 2025

What this trial tests

Phase 1 trial testing CYR-064 in Hyposmia. Withdrawn.

Timeline

1 April 2025

Primary endpoint
1 June 2026

1 July 2026

Quick facts

Lead sponsor	University of Nebraska
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 April 2025
Primary completion	1 June 2026
Estimated completion	1 July 2026

Drugs / interventions tested

CYR-064 — full drug profile →

Conditions studied

Hyposmia — all drugs for Hyposmia →
Anosmia — all drugs for Anosmia →

Sponsor

University of Nebraska

Who can join

Adults 19 to 80, any sex, with Hyposmia or Anosmia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Numeric Rating Scale-11 Smell-Patient Reported Outcome (PRO) (NRS-11-PRO): Improvement
Time frame: baseline to week 24
Improvement in patient-reported paper diary (scale 0-10). Score of 0="I cannot smell anything", to 10="My sense of smell is normal to me"
Numeric Rating Scale-11 Taste-Patient Reported Outcome (PRO) (NRS-11-PRO): Improvement
Time frame: baseline to week 24
Improvement in patient-reported paper diary (scale 0-10). Score of 0="I could not taste food", to 10="My food tastes normal to me"
Numeric Rating Scale-11 Smell-Patient Reported Outcome (PRO) (NRS-11-PRO): Mean Change
Time frame: baseline to week 24
Mean Change in patient-reported paper diary (scale 0-10) of sense of smell. Score of 0="I cannot smell anything", to 10="My sense of smell is normal to me"
Numeric Rating Scale-11 Taste-Patient Reported Outcome (PRO) (NRS-11-PRO): Mean Change
Time frame: baseline to week 24
Mean Change in patient-reported paper diary (scale 0-10) of ability to taste food. Score of 0="I could not taste food", to 10="My food tastes normal to me"

Sponsor's own description

The goal of this study is to learn if intranasal theophylline (CYR-064) improves sense of smell in participants with hyposmia or anosmia related to the onset of Parkinson's Disease. Fifteen adults, age 19-80, years will participate for about 32 weeks. They will use the study nasal spray for 24 weeks. The nasal spray is given as 2 sprays to each side of the nose twice per day. They will be seen every 2 weeks during the first month of treatment, followed by monthly in-person visits. Tests about memory, Parkinson's Disease symptoms, and ability to detect and identify smells will be completed. Participants are monitored for any side effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.
Qiu Y, Huang S, Peng L, Yang L, et al · · 2025 · cited 18× · PMID 40487748 · DOI 10.1002/mco2.70213

Verify or expand the search:

Other trials of CYR-064

Trials testing the same drug.

NCT06019000 — Study of CYR-064 Versus Placebo in Patients. · Phase 2 · completed

Other recruiting trials for Hyposmia

Currently open trials in the same condition.

NCT06733636 — Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults · NA · recruiting
NCT06817499 — Treatment of Olfactory Dysfunction Using Vagus Nerve Stimulation · NA · active not recruiting
NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06498687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 12 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06498687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing